anti-atopic

GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.

Clobetasone butyrate, a synthetic glucocorticoid with topical anti-inflammatory activity, is effective in treating corticosteroid-responsive dermatoses, such as atopic dermatitis and psoriasis, especially within skin tissues.

Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug developed for the treatment of skin diseases.

Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders.

1. Eriodictyol (Huazhongilexone) is a flavonoid with anti-inflammatory and antioxidant activities. 2. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance. 3. Eriodictyol may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis.

Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated IgG1 anti-OX40 monoclonal antibody indicated for atopic dermatitis (AD) research [1].

Lokivetmab, an Anti-Canine IL31 Recombinant Antibody, is a monoclonal antibody targeting canine IL-31, utilized in research related to atopic dermatitis (AD) in dogs [1].

Apamistamab (Anti-CD45 antibody) is a humanized antibody targeting CD45, which can be used to study atopic dermatitis.

Benvitimod is a non-steroidal anti-inflammatory drug (NSAID) potentially for the treatment of atopic dermatitis.

Pimecrolimus (SDZ-ASM 981), a calcineurin inhibitor immunosuppressant, binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin.

JAK1 STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1 STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1 STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1 JAK1 and p-STAT3 STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).

As a tricyclic antidepressant, Doxepin inhibits the reuptake of serotonin and norepinephrine. Doxepin shows therapeutic effects on atopic dermatitis and chronic urticaria that also improves cognitive processes as well as protect the central nervous system. Doxepin has anti-inflammatory effects and reduces oxidative stress[1] [2] [3].

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).

Mapracorat (ZK-245186, BOL-303242X) is a selective glucocorticoid receptor agonist commonly used as an anti-inflammatory agent for atopic dermatitis, post-cataract surgery inflammation, and allergic conjunctivitis.

Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1 Th17 and neutrophil pathways. Spesolimab can be used to study systemic pustular psoriasis, palmar and plantar impetigo (PPP), and atopic dermatitis.